Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology

– Akari will host an analyst and investor symposium on Saturday, Dec 3 – NEW YORK and LONDON, November 3rd, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been accepted at the 58th Annual Meeting of the American Society of Hematology in San Diego, CA, from December 3-6, 2016. Abstract publication number 5900 entitled, “Therapeutic Development of Complement C5 inhibitor CoversinTM with Extended Half-life via PASylation®,” details the modifications made to extend the half-life of Coversin from a self-administered once-daily subcutaneous injection to potential weekly dosing for enhanced patient convenience. The abstract authors are Miles Nunn, Chief Scientific Officer of Akari Therapeutics and Arne Skerra, Chairman & Founder of XL-protein GmbH. The abstract also provides an update on the first PNH patient on unmodified Coversin therapy who is eculizumab resistant. This patient has now been treated for more than 8 months and continues to respond well to treatment. Click here to see full release

The release as fetched from its publisher. akaritx.com ↗